RTEL1-TNFRSF6B: A Potential Drug Target and Biomarker (G100533107)

RTEL1-TNFRSF6B: A Potential Drug Target and Biomarker

RTEL1 (Ring-type LIM gene 1) and its associated protein, NFRSF6B (Nrf2-Regulated gene 6), have been identified as potential drug targets and biomarkers for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The RTEL1 gene is a member of the LIM gene family, which is known for its role in regulating cell death and cell plasticity. NFRSF6B is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been associated with various diseases.

Recent studies have suggested that RTEL1 and NFRSF6B may be involved in the development and progression of certain diseases, including cancer. For example, studies have shown that high levels of RTEL1 expression are associated with poor prognosis in cancer patients. Additionally, NFRSF6B has been shown to be involved in the regulation of cell apoptosis, which is a natural mechanism of cell death that helps prevent the spread of cancer.

Due to these potential connections, RTEL1 and NFRSF6B have been identified as potential drug targets and biomarkers for cancer. Researchers are currently exploring the use of small molecules and other compounds to target RTEL1 and NFRSF6B and to test their effectiveness in treating various diseases.

One approach to targeting RTEL1 and NFRSF6B is to use small molecules that can modulate their expression or activity. This can be done by binding to specific RNA molecules within the gene and preventing them from interacting with the protein. One example of a small molecule that has been shown to interact with RTEL1 is 2-methoxybenzaldehyde (2-MB), which has been shown to inhibit the activity of the protein and reduce the amount of NFRSF6B produced.

Another approach to targeting RTEL1 and NFRSF6B is to use antibodies that recognize specific proteins within the gene. This can be done by using antibodies that recognize the protein and then using them to block its activity. One example of an antibody that has been shown to effectively block the activity of NFRSF6B is an anti-NFRSF6B monoclonal antibody (mAb), which has been shown to effectively inhibit the activity of the protein and reduce its levels in cancer cells.

While the use of small molecules and antibodies to target RTEL1 and NFRSF6B is still in its early stages, it holds great promise as a potential drug target and biomarker for cancer. Further research is needed to fully understand the mechanisms by which these molecules interact with the protein and to develop safe and effective treatments.

Protein Name: RTEL1-TNFRSF6B Readthrough (NMD Candidate)

The "RTEL1-TNFRSF6B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTEL1-TNFRSF6B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTF1 | RTF2 | RTKN | RTKN2 | RTL1 | RTL10 | RTL3 | RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1